All R&D funders, developers and manufacturers must help ensure that new vaccines, diagnostics and treatments developed for COVID-19 are globally available, appropriate and affordable, regardless of where they have been developed or who has funded them. The COVID-19 virus has now reached every corner of the world – these products must also.
At least $8 billion of new funding is needed for the global response to COVID-19 – for research, development and supply of treatments for all, and support for public health measures in countries with the weakest health systems.
Research is an essential part of being ready for and responding to public health emergencies, like COVID-19 and Ebola.
Wellcome is working with the World Health Organization (WHO) to take on big challenges in global health.
We support researchers across the world to explore fundamental questions about health and disease.
Over the past ten years, we’ve invested more than £120 million in longitudinal population studies in the UK and low- and middle-income countries.
This report aims to guide experts, communicators and practitioners to communicate with impact, so that the public understands and supports action on drug-resistant infections.
[Summary] This report aims to help experts and practitioners to communicate with impact, so that the public understands and supports action on drug-resistant infections.
Advancing epidemics R&D to keep up with a changing world
This paper examines the status, progress and challenges in research and development for epidemics. It was developed to feed into the first annual report of the Global Preparedness Monitoring Board.